Diamicron
(Gliclazide)PreclinicalSmall molecule
Merck & Co.Gliclazide is used to help control blood sugar levels in people with type 2 diabetes by stimulating the pancreas to produce more insulin.[1] Diamicron is currently being investigated across 2 indications[3], with its most advanced program in Preclinical.[1]
Diamicron is one of 97 small molecule programs targeting Cognitive impairment. It is currently in Preclinical.
2
Indications
24
Total Trials
2
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
111 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Actos
TakedaApproved
Glucophage
EMD SeronoApproved
Onglyza
AstraZenecaApproved
Estrace
Novo NordiskApproved
Prograf
VVeloxis Pharmaceuticals
Approved
Viagra
VViatris Specialty LLC
Approved
Flovent
PParatek Pharmaceuticals Inc
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes7 trials
Show 4 more trials
T2DM2 trials
Interaction2 trials
Tics2 trials
9 more indications
Adverse Reaction1 trial
Safety Evaluation of Adverse Reactions in Diabetes
Completed·—·Phase 4·NCT02092597·42 enrolled
Endothelial Dysfunction1 trial
Type 2 Diabetic Patients1 trial
Safety and Efficacy1 trial
ESS1 trial
Type 2 Diabetes Mellitus1 trial
Cognitive impairment1 trial
Unspecified2 trials
Antidiabetic Effects on Intrahepatic Fat
Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT03068065·87 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gliclazide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sulfonylurea Receptor 1, Kir6.2 Blocker[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company